Celltrion Pharm Inc (068760) — Cash Flow-to-Debt Ratio
Celltrion Pharm Inc (068760) has a Cash Flow-to-Debt Ratio of 0.07x as of September 2025, meaning its operating cash flow of ₩23.44 Billion could theoretically repay 0% of its total liabilities (₩319.38 Billion) in one year. Explore Celltrion Pharm Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Celltrion Pharm Inc Cash Flow-to-Debt Ratio (2014–2024)
Historical debt coverage capacity for Celltrion Pharm Inc across 11 annual periods. Also explore 068760 asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Celltrion Pharm Inc (2014–2024)
Year-by-year debt coverage analysis for Celltrion Pharm Inc. For market capitalisation and broader financial context, see 068760 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩56.59 Billion | ₩272.54 Billion | ▲ +528.3% |
| 2023 | 0.03x | ₩8.76 Billion | ₩264.98 Billion | ▲ +298.4% |
| 2022 | -0.02x | ₩-4.05 Billion | ₩242.94 Billion | ▼ -105.5% |
| 2021 | 0.30x | ₩93.15 Billion | ₩305.92 Billion | ▲ +107.9% |
| 2020 | 0.15x | ₩36.25 Billion | ₩247.51 Billion | ▲ +0.4% |
| 2019 | 0.15x | ₩27.85 Billion | ₩190.95 Billion | ▲ +85.9% |
| 2018 | 0.08x | ₩14.31 Billion | ₩182.41 Billion | ▲ +236.4% |
| 2017 | -0.06x | ₩-10.16 Billion | ₩176.65 Billion | ▲ +37.5% |
| 2016 | -0.09x | ₩-15.21 Billion | ₩165.37 Billion | ▼ -258.7% |
| 2015 | 0.06x | ₩13.36 Billion | ₩230.54 Billion | ▼ -34.2% |
| 2014 | 0.09x | ₩17.33 Billion | ₩196.74 Billion | — |